×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
INSM – insmed incorporated (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
INSM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/24
08:42 am
insm
Insmed eyes Arikayce label expansion on Phase IIIb lung disease success [Yahoo! Finance]
Low
Report
Insmed eyes Arikayce label expansion on Phase IIIb lung disease success [Yahoo! Finance]
3/24
08:30 am
insm
Insmed (INSM) had its price target raised by Bank of America Corporation from $211.00 to $213.00. They now have a "buy" rating on the stock.
Low
Report
Insmed (INSM) had its price target raised by Bank of America Corporation from $211.00 to $213.00. They now have a "buy" rating on the stock.
3/23
09:35 pm
insm
A Look At Insmed (INSM) Valuation After Positive ENCORE Phase 3b ARIKAYCE Data [Yahoo! Finance]
Low
Report
A Look At Insmed (INSM) Valuation After Positive ENCORE Phase 3b ARIKAYCE Data [Yahoo! Finance]
3/23
05:59 pm
insm
Insmed CEO on its Arikayce drug after shares surge on trial results [CNBC]
Low
Report
Insmed CEO on its Arikayce drug after shares surge on trial results [CNBC]
3/23
12:45 pm
insm
Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript [Seeking Alpha]
Low
Report
Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript [Seeking Alpha]
3/23
12:32 pm
insm
Insmed ENCORE Phase 3 Trial Hits Primary Endpoint; ARIKAYCE Drives Strong MAC Culture Conversion Gains [Yahoo! Finance]
Low
Report
Insmed ENCORE Phase 3 Trial Hits Primary Endpoint; ARIKAYCE Drives Strong MAC Culture Conversion Gains [Yahoo! Finance]
3/23
10:27 am
insm
Insmed shares rise on positive late-stage trial results for lung disease therapy [Yahoo! Finance]
Low
Report
Insmed shares rise on positive late-stage trial results for lung disease therapy [Yahoo! Finance]
3/23
09:49 am
insm
Insmed (INSM) had its price target lowered by Wells Fargo & Company from $208.00 to $175.00. They now have an "overweight" rating on the stock.
Low
Report
Insmed (INSM) had its price target lowered by Wells Fargo & Company from $208.00 to $175.00. They now have an "overweight" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/23
07:01 am
insm
Form 8-K INSMED Inc For: Mar 23
Low
Report
Form 8-K INSMED Inc For: Mar 23
3/20
04:05 pm
insm
Form 4 INSMED Inc For: Mar 19 Filed by: Lewis William
Medium
Report
Form 4 INSMED Inc For: Mar 19 Filed by: Lewis William
3/19
04:57 pm
insm
Form 144 INSMED Inc Filed by: Lewis William
Medium
Report
Form 144 INSMED Inc Filed by: Lewis William
3/5
05:00 pm
insm
Form 144 INSMED Inc Filed by: Lewis William
Low
Report
Form 144 INSMED Inc Filed by: Lewis William
3/5
04:17 pm
insm
Form 4 INSMED Inc For: Mar 05 Filed by: Lewis William
Low
Report
Form 4 INSMED Inc For: Mar 05 Filed by: Lewis William
3/5
04:15 pm
insm
Form 4 INSMED Inc For: Mar 03 Filed by: SHAROKY MELVIN MD
Low
Report
Form 4 INSMED Inc For: Mar 03 Filed by: SHAROKY MELVIN MD
2/27
04:19 pm
insm
Form 4 INSMED Inc For: Feb 25 Filed by: SHAROKY MELVIN MD
Low
Report
Form 4 INSMED Inc For: Feb 25 Filed by: SHAROKY MELVIN MD
2/25
04:05 pm
insm
Form 4 INSMED Inc For: Feb 24 Filed by: Smith Michael Alexander
Low
Report
Form 4 INSMED Inc For: Feb 24 Filed by: Smith Michael Alexander
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/3
Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis
40.6%
2/4 Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Goldman Sachs Group Inc from $33.00 to $46.00. They now have a "buy" rating on the stock. 12.6%
3/17 Insmed Incorporated (NASDAQ: INSM) had its price target lowered by analysts at Stifel Nicolaus from $55.00 to $45.00. They now have a "buy" rating on the stock. 12.6%
4/30 Insmed Reports First Quarter 2020 Financial Results and Provides Business Update 8.0%
10/11 Insmed Incorporated (NASDAQ: INSM) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 7.9%
4/2 Insmed Appoints Carol A. Schafer to its Board of Directors 7.1%
10/30 Form 10-Q INSMED Inc For: Sep 30 6.7%
4/20 Insmed to Host First Quarter 2020 Financial Results Conference Call on Thursday, April 30, 2020 6.5%
1/7 Form 4 INSMED Inc For: Jan 03 Filed by: SORIANO JOHN 6.1%
6/12 Form 3 INSMED Inc For: Jun 03 Filed by: GOLL JOHN 5.7%
2/4 Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Goldman Sachs Group Inc from $33.00 to $46.00. They now have a "buy" rating on the stock. 12.6%
3/17 Insmed Incorporated (NASDAQ: INSM) had its price target lowered by analysts at Stifel Nicolaus from $55.00 to $45.00. They now have a "buy" rating on the stock. 12.6%
4/30 Insmed Reports First Quarter 2020 Financial Results and Provides Business Update 8.0%
10/11 Insmed Incorporated (NASDAQ: INSM) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 7.9%
4/2 Insmed Appoints Carol A. Schafer to its Board of Directors 7.1%
10/30 Form 10-Q INSMED Inc For: Sep 30 6.7%
4/20 Insmed to Host First Quarter 2020 Financial Results Conference Call on Thursday, April 30, 2020 6.5%
1/7 Form 4 INSMED Inc For: Jan 03 Filed by: SORIANO JOHN 6.1%
6/12 Form 3 INSMED Inc For: Jun 03 Filed by: GOLL JOHN 5.7%
TOP News Decliners
2/25
Q4/2019 12/31/2019 EPS -0.590 ZacksConsensus -0.590 ActVsEst 0.000 - In-Line
-16.4%
5/7 Q1/2019 3/31/2019 EPS -0.960 ZacksConsensus -0.940 ActVsEst (0.020) - Miss -13.0%
8/1 Q2/2019 6/30/2019 EPS -0.810 ZacksConsensus -0.850 ActVsEst 0.040 - Beat -12.3%
2/26 Galapagos Ratings Downgrade, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] -8.1%
3/31 Form DEFA14A INSMED Inc -6.6%
8/2 Insmed, Inc. (INSM) CEO Will Lewis on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.1%
5/20 New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease -5.9%
3/7 Insmed Incorporated (NASDAQ: INSM) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -5.9%
3/5 Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -5.7%
1/16 Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at JMP Securities. They now have a $40.00 price target on the stock. -5.0%
5/7 Q1/2019 3/31/2019 EPS -0.960 ZacksConsensus -0.940 ActVsEst (0.020) - Miss -13.0%
8/1 Q2/2019 6/30/2019 EPS -0.810 ZacksConsensus -0.850 ActVsEst 0.040 - Beat -12.3%
2/26 Galapagos Ratings Downgrade, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha] -8.1%
3/31 Form DEFA14A INSMED Inc -6.6%
8/2 Insmed, Inc. (INSM) CEO Will Lewis on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.1%
5/20 New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease -5.9%
3/7 Insmed Incorporated (NASDAQ: INSM) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -5.9%
3/5 Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -5.7%
1/16 Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at JMP Securities. They now have a $40.00 price target on the stock. -5.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: